Histological indicators of prognosis in glioblastomas: Retinoblastoma protein expression and oligodendroglial differentiation indicate improved survival

Histopathology

Volumn 44, Issue 6, 2004, Pages 555-560

  Hilton, D A ^a   Penney, M ^a   Pobereskin, L ^a   Sanders, H ^b   Love, S ^c  

^a DERRIFORD HOSPITAL   (United Kingdom)

^b UNIVERSITY OF PLYMOUTH   (United Kingdom)

^c FRENCHAY HOSPITAL   (United Kingdom)

Author keywords

Chromosome 10; DCC; Glioblastoma; Prognosis; Retinoblastoma; Survival

Indexed keywords

ARTICLE; CHROMOSOME 10; CHROMOSOME LOSS; COLON CANCER; CONTROLLED STUDY; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; OLIGODENDROGLIA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETINOBLASTOMA; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TUMOR DIFFERENTIATION;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; CELL ADHESION MOLECULES; CELL DIFFERENTIATION; CHROMOSOMES, HUMAN, PAIR 10; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LOSS OF HETEROZYGOSITY; MIDDLE AGED; OLIGODENDROGLIA; PROGNOSIS; RECEPTORS, CELL SURFACE; RETINOBLASTOMA PROTEIN; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEINS;

EID: 3042682951     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2004.01887.x     Document Type: Article

References (22)

1. Scott JN, Rewcastle NB, Brasher PM et al. Which glioblastoma multiforme patient will become a long-term survivor? A population-based study. Ann. Neurol. 1999; 46; 183-188.
2. Davies E, Hopkins A. Malignant cerebral glioma I. Survival, disability and morbidity after radiotherapy. Br. Med. J. 1996; 313; 1507-1512.
3. Balesaria S, Brock C, Bower M et al. Loss of chromosome 10 is an independent prognostic factor in high-grade gliomas. Br. J. Cancer 1999; 81; 1371-1377.
4. Dalrymple SJ, Herath JF, Ritland SR, Moertel CA, Jenkins RB. Use of fluorescence in situ hybridisation to detect loss of chromosome 10 in astrocytomas. J. Neurosurg. 1995; 83; 316-323.
5. Schmidt MC, Antweiler S, Urban N et al. Impact of genotype and morphology on the prognosis of glioblastoma. J. Neuropathol. Exp. Neurol. 2002; 61; 321-328.
6. Tada K, Shiraishi S, Kamiryo T et al. Analysis of loss of heterozygosity on chromosome 10 in patients with malignant astrocytic tumor: correlation with patient age and survival. J. Neurosurg. 2001; 95; 651-659.
7. Horiguchi H, Hirose T, Sano T, Nagahiro S. Loss of chromosome 10 in glioblastoma: relation to proliferation and angiogenesis. Pathol. Int. 1999; 49; 681-686.
8. Burns KL, Ueki K, Jhung SL, Koh J, Louis DN. Molecular correlates of p16, cdk4, and pRb immunohistochemistry in glioblastomas. J. Neuropathol. Exp. Neurol. 1998; 57; 122-130.
9. Nakamura M, Konishi N, Tsunoda S et al. Retinoblastoma protein expression and MIB-1 correlate with survival of patients with malignant astrocytoma. Cancer 1997; 80; 242-249.
10. Puduvalli VK, Kyritsis AP, Hess KR et al. Patterns of expression of Rb and p16 in astrocytic gliomas, and correlation with survival. Int. J. Oncol. 2000; 17; 963-969.
11. Von Deimling A, Fimmers R, Schmidt MC et al. Comprehensive allotype and genotype analysis of 466 human nervous system tumors. J. Neuropathol. Exp. Neurol. 2000; 59; 544-558.
12. Meyerhardt JA, Caca K, Eckstrand BC et al. Netrin-1: interaction with deleted in colorectal cancer (DCC) and alterations in brain tumours and neuroblastomas. Cell Growth Differ. 1999; 10; 35-42.
13. Chen YQ, Hsieh JT, Yao F et al. Induction of apoptosis and G2/M cell cycle arrest by DCC. Oncogene 1999; 18; 2747-2754.
14. Reyes-Mugica M, Reiger-Christ K, Ohgaki H et al. Loss of DCC expression and glioma progression. Cancer Res. 1997; 57; 382-386.
15. Kleihues P, Cavenee WK. Pathology and genetics of tumours of the nervous system. Lyon: IARC Press, 2000.
16. He J, Mokhtari K, Sanson M et al. Glioblastomas with an oligodendroglial component: a pathological and molecular study. J. Neuropathol. Exp. Neurol. 2001; 60; 863-871.
17. Kraus JA, Lamszus K, Glesmann N et al. Molecular genetic alterations in glioblastomas with oligodendroglial component. Acta Neuropathol. 2001; 101; 311-320.
18. Smith JS, Perry AP, Borell TJ et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas and mixed oligoastrocytomas. J. Clin. Oncol. 2000; 18; 636-645.
19. Hilton DA, Penney M, Evans B, Sanders H, Love S. Evaluation of molecular markers in low-grade diffuse astrocytomas: loss of p16 and retinoblastoma protein expression is associated with short survival. Am. J. Surg. Pathol. 2002; 26; 472-478.
20. Kirla R., Salminen E, Huhtala S, Nuutinen J, Talve L. Prognostic value of the expression of tumor suppressor genes p53, p21, p16 and pRb and Ki-67 labeling in high grade astrocytomas treated with radiotherapy. J. Neurooncol. 2000; 46; 71-80.
21. Hara A, Saegusa M, Mikami T, Okayasu I. Loss of DCC expression in astrocytomas: relation to p53 abnormalities, cell kinetics, and survival. J. Clin. Pathol. 2001; 54; 860-865.
22. Nakatani K, Yoshimi N, Mori H et al. The significance of the expression of tumor suppressor gene DCC in human gliomas. J. Neurooncol. 1998; 40; 237-242.